Valuation: Alcon

Market Cap 33.41B 29.21B 26.84B 25.02B 47.46B 3,181B 48.18B 322B 125B 1,564B 125B 123B 5,389B P/E 2026 *
31.7x
P/E 2027 * 24.7x
Enterprise Value 36.01B 31.48B 28.93B 26.96B 51.14B 3,428B 51.92B 347B 135B 1,685B 135B 132B 5,807B EV / Sales 2026 *
3.23x
EV / Sales 2027 * 2.96x
Free-Float
97.36%
Yield 2026 *
0.52%
Yield 2027 * 0.6%
Manager TitleAgeSince
Chief Executive Officer 60 30/06/2018
Director of Finance/CFO 58 07/04/2019
Chief Tech/Sci/R&D Officer - 31/12/2024
Director TitleAgeSince
Director/Board Member 60 -
Chairman 70 30/06/2018
Director/Board Member 63 31/01/2019
Change 5-day change 1-year change 3-year change Capi.($)
+16.82%0.00% - - 33.41B
+0.52%+5.81%-26.97%+2.29% 90.56B
-2.96%+1.21%-1.42%-23.09% 14.47B
+0.59%+5.99% - - 9.73B
+1.77%+14.75%-5.97%+617.19% 2.24B
+1.74%+6.95%-27.72%-64.96% 1.46B
+7.35%+15.68%+23.96%+1.64% 895M
+1.76%+8.51%-37.49%-28.09% 856M
-0.12%+0.59%+48.65%-29.04% 784M
+0.73%-11.43% - - 640M
Average +1.18%+5.38%-3.85%+67.99% 13.51B
Weighted average by Cap. +0.21%+2.96%-22.38%+10.01%

Financials

2026 *2027 *
Net sales 11.14B 9.74B 8.95B 8.34B 15.82B 1,061B 16.06B 107B 41.77B 521B 41.82B 40.92B 1,797B 11.82B 10.33B 9.5B 8.85B 16.79B 1,125B 17.04B 114B 44.32B 553B 44.37B 43.41B 1,906B
Net income 1.11B 974M 895M 834M 1.58B 106B 1.61B 10.74B 4.18B 52.12B 4.18B 4.09B 180B 1.38B 1.21B 1.11B 1.03B 1.96B 131B 1.99B 13.31B 5.17B 64.58B 5.18B 5.07B 223B
Net Debt 2.6B 2.27B 2.09B 1.94B 3.69B 247B 3.74B 25.03B 9.73B 121B 9.74B 9.53B 419B 1.54B 1.35B 1.24B 1.15B 2.19B 147B 2.22B 14.86B 5.78B 72.1B 5.78B 5.66B 248B
Logo Alcon
Alcon Inc. is the global leader in the design, manufacture and marketing of ophthalmic care products. Net sales break down by category of products as follows: - ophthalmic surgical products and equipment (55.7%): consumables (52.7% of net sales), implantable products (31%) and other products (16.3%; in particular surgical equipment) for the treatment of cataracts, retinal diseases, glaucoma and refractive errors; - vision care products (44.3%): contact lenses (60.6% of sales) and eye care products (39.4%; eye drops and ophthalmic ointments, etc.). At the end of 2025, the group operated 17 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (0.7%), the United States (45.1%), Japan (5.9%), China (5.5%), and Other (42.8%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA